A Phase 2 Intensification Study of BIT225, a Human Immunodeficiency Virus-1 Vpu Inhibitor, in HIV-1 Infected Individuals Initiating Combination Antiretroviral Therapy (cART).
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs BIT 225 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Biotron
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 According to a Biotron media release, the trial is in progress and scheduled for completion in the second half of 2017.
- 31 Jul 2017 Planned End Date changed from 31 Oct 2017 to 4 Jan 2018.